Theratechnologies Inc
THTX
View Detailed Chart
3.390USD
0.000
Market hours （ET）Quotes delayed by 15 min
155.87MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+33.99%
Year to Date
+87.29%
1 Year
+89.39%
View Detailed Chart
TradingKey Stock Score of Theratechnologies Inc
Currency: USD Updated: 2025-09-25Key Insights
Theratechnologies Inc's fundamentals are relatively healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Theratechnologies Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
7.250
Target Price
+113.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Theratechnologies Inc Highlights
StrengthsRisks
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Growing
The company is in a growing phase, with the latest annual income totaling USD 85.87M.
Undervalued
The company’s latest PE is -18.27, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 22.32M shares, decreasing 4.58% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.45.
Theratechnologies Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Theratechnologies Inc Info
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Ticker SymbolTHTX
CompanyTheratechnologies Inc
CEOMr. Paul Levesque
Websitehttps://www.theratech.com/
FAQs
What is the current price of Theratechnologies Inc (THTX)?
The current price of Theratechnologies Inc (THTX) is 3.390.
What is the symbol of Theratechnologies Inc?
The ticker symbol of Theratechnologies Inc is THTX.
What is the 52-week high of Theratechnologies Inc?
The 52-week high of Theratechnologies Inc is 4.730.
What is the 52-week low of Theratechnologies Inc?
The 52-week low of Theratechnologies Inc is 1.590.
What is the market capitalization of Theratechnologies Inc?
The market capitalization of Theratechnologies Inc is 155.87M.
What is the net income of Theratechnologies Inc?
The net income of Theratechnologies Inc is -8.31M.
Is Theratechnologies Inc (THTX) currently rated as Buy, Hold, or Sell?
According to analysts, Theratechnologies Inc (THTX) has an overall rating of --, with a price target of 7.250.
What is the Earnings Per Share (EPS TTM) of Theratechnologies Inc (THTX)?
The Earnings Per Share (EPS TTM) of Theratechnologies Inc (THTX) is -0.186.
Related Instruments
-0.29%
+0.45%
+0.67%
+0.20%
+0.61%
+2.87%
+1.12%
-0.27%
-0.17%
+0.28%
-0.51%
+0.13%
+0.82%
-0.23%
+0.06%
+0.71%
+1.81%
0.00%
+0.90%
+1.66%Popular Symbols
